Effective mosaic-based nanovaccines against avian influenza in poultry

Kingstad-Bakke, Brock; Chandrasekar, S; Phanse, Yashdeep; Ross, Kathleen A.; Hatta, Masato; Suresh, M.; Kawaoka, Yoshihiro; Osorio, Jorge E.; Narasimhan, Balaji; Talaat, Adel M.

doi:10.1016/j.vaccine.2019.06.077

Cited by 18 publications

(17 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subsequent research examined the immunogenicity stimulation with nanovaccine consisting of polyanhydride NPs encapsulating HA (H5M) antigen. The study confirmed the immunogenic potential of the nanovaccine, as level of immune responses against the H5N1 and H5N2 strains was significantly increased [49].…”

Section: Hemagglutinin Protein As a Viral Antigen In Vaccine Based Onsupporting

confidence: 70%

Anti-Influenza Strategies Based on Nanoparticle Applications

2020

View full text Add to dashboard Cite

Influenza virus has the potential for being one of the deadliest viruses, as we know from the pandemic’s history. The influenza virus, with a constantly mutating genome, is becoming resistant to existing antiviral drugs and vaccines. For that reason, there is an urgent need for developing new therapeutics and therapies. Despite the fact that a new generation of universal vaccines or anti-influenza drugs are being developed, the perfect remedy has still not been found. In this review, various strategies for using nanoparticles (NPs) to defeat influenza virus infections are presented. Several categories of NP applications are highlighted: NPs as immuno-inducing vaccines, NPs used in gene silencing approaches, bare NPs influencing influenza virus life cycle and the use of NPs for drug delivery. This rapidly growing field of anti-influenza methods based on nanotechnology is very promising. Although profound research must be conducted to fully understand and control the potential side effects of the new generation of antivirals, the presented and discussed studies show that nanotechnology methods can effectively induce the immune responses or inhibit influenza virus activity both in vitro and in vivo. Moreover, with its variety of modification possibilities, nanotechnology has great potential for applications and may be helpful not only in anti-influenza but also in the general antiviral approaches.

show abstract

Section: Hemagglutinin Protein As a Viral Antigen In Vaccine Based Onsupporting

confidence: 70%

Anti-Influenza Strategies Based on Nanoparticle Applications

2020

View full text Add to dashboard Cite

show abstract

“…Mucosal vaccination strategies such as intranasal vaccinations could be an effective therapeutic strategy against COVID-19 by mediating the induction of local and systemic immune responses. Although appealing, formulating intranasal vaccinations can be challenging owing to the low bioavailability, antigen uptake, and antigen degradation at mucosal surfaces [36,37]. Previously, we detailed the development of the QAC adjuvant system for efficient intranasal delivery of DNA immunogens, circumventing some of the challenges observed with I.N vaccination [11].…”

Section: Discussionmentioning

confidence: 99%

Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization

et al. 2021

Self Cite

View full text Add to dashboard Cite

The rapid transmission of SARS-CoV-2 in the USA and worldwide necessitates the development of multiple vaccines to combat the COVID-19 global pandemic. Previously, we showed that a particulate adjuvant system, quil-A-loaded chitosan (QAC) nanoparticles, can elicit robust immunity combined with plasmid vaccines when used against avian coronavirus. Here, we report on the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens. Only the heterologous intranasal immunization strategy elicited neutralizing antibodies against SARS-CoV-2 in serum and bronchoalveolar lavage of mice, suggesting a protective vaccine. The same prime/boost strategy led to the induction of type 1 and type 17 T-cell responses and polyfunctional T-cells expressing multiple type 1 cytokines (e.g., IFN-γ, TNFα, IL-2) in the lungs and spleens of vaccinated mice. In contrast, the plasmid homologous vaccine strategy led to the induction of local mono and polyfunctional T-cells secreting IFN-γ. Outcomes of this study support the potential of QAC-nano vaccines to elicit significant mucosal immune responses against respiratory coronaviruses.

show abstract

“…The disease is prevalent worldwide and often associated with important economic losses among broilers and layers. Moreover, due to its zoonotic potential, it can threaten human life with looming pandemic potential [94]. In endemic regions, besides biosecurity, the specific immunoprophylaxis measures remain the most important means of disease prevention and control.…”

Section: Influenza Antigens Encapsulated In Plga Npsmentioning

confidence: 99%

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

et al. 2021

View full text Add to dashboard Cite

The field of veterinary medicine needs new solutions to address the current challenges of antibiotic resistance and the need for increased animal production. In response, a multitude of delivery systems have been developed in the last 20 years in the form of engineered nanoparticles (ENPs), a subclass of which are polymeric, biodegradable ENPs, that are biocompatible and biodegradable (pbENPs). These platforms have been developed to deliver cargo, such as antibiotics, vaccines, and hormones, and in general, have been shown to be beneficial in many regards, particularly when comparing the efficacy of the delivered drugs to that of the conventional drug applications. However, the fate of pbENPs developed for veterinary applications is poorly understood. pbENPs undergo biotransformation as they are transferred from one ecosystem to another, and these transformations greatly affect their impact on health and the environment. This review addresses nanoparticle fate and impact on animals, the environment, and humans from a One Health perspective.

show abstract

Effective mosaic-based nanovaccines against avian influenza in poultry

Cited by 18 publications

References 54 publications

Anti-Influenza Strategies Based on Nanoparticle Applications

Anti-Influenza Strategies Based on Nanoparticle Applications

Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

Contact Info

Product

Resources

About